Abaxis (ABAX) Receives Daily Coverage Optimism Rating of 0.30

News articles about Abaxis (NASDAQ:ABAX) have been trending positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abaxis earned a coverage optimism score of 0.30 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 46.5648836472424 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s analysis:

Several analysts recently commented on ABAX shares. UBS Group raised shares of Abaxis from an “underperform” rating to a “market perform” rating in a report on Tuesday, January 9th. BidaskClub raised shares of Abaxis from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Zacks Investment Research raised shares of Abaxis from a “hold” rating to a “buy” rating and set a $85.00 price target for the company in a report on Tuesday, January 30th. Stifel Nicolaus upped their price target on shares of Abaxis from $48.00 to $57.00 and gave the stock a “hold” rating in a report on Friday, January 26th. Finally, Raymond James Financial upgraded shares of Abaxis from an “underperform” rating to a “market perform” rating in a research report on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $62.30.

Shares of Abaxis (NASDAQ ABAX) traded up $1.06 during midday trading on Wednesday, reaching $73.74. 102,539 shares of the company traded hands, compared to its average volume of 201,956. The company has a market capitalization of $1,670.00, a price-to-earnings ratio of 60.94, a PEG ratio of 12.17 and a beta of 1.27. Abaxis has a fifty-two week low of $43.66 and a fifty-two week high of $78.53.

Abaxis (NASDAQ:ABAX) last released its quarterly earnings data on Thursday, January 25th. The medical research company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.05. The firm had revenue of $59.70 million for the quarter, compared to analyst estimates of $59.37 million. Abaxis had a net margin of 10.51% and a return on equity of 10.09%. The business’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period last year, the firm earned $0.30 earnings per share. analysts predict that Abaxis will post 1.2 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Thursday, March 1st will be issued a $0.16 dividend. The ex-dividend date is Wednesday, February 28th. This represents a $0.64 annualized dividend and a dividend yield of 0.87%. Abaxis’s dividend payout ratio is currently 52.89%.

In other news, Director Michael D. Casey sold 5,000 shares of Abaxis stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $71.07, for a total value of $355,350.00. Following the completion of the transaction, the director now owns 27,290 shares in the company, valued at $1,939,500.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Donald Peter Wood sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $68.99, for a total transaction of $689,900.00. The disclosure for this sale can be found here. Insiders have sold 25,662 shares of company stock valued at $1,804,604 in the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

WARNING: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/14/abaxis-abax-earning-positive-media-coverage-analysis-finds/1890510.html.

Abaxis Company Profile

Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.

Insider Buying and Selling by Quarter for Abaxis (NASDAQ:ABAX)

Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.